UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib

Annals of oncology, 2008-11, Vol.19 (11), p.1955-1961

2008

Volltextzugriff (PDF)

Immune‐related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors

British journal of dermatology (1951), 2017-06, Vol.176 (6), p.1649-1652

2017

Volltextzugriff (PDF)

Validation and responsiveness of the English version of the Chemotherapy-Induced Alopecia Distress Scale (CADS) in breast cancer patients

Supportive care in cancer, 2024-06, Vol.32 (6), p.369-369, Article 369

2024

Volltextzugriff (PDF)

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies

Annals of oncology, 2015-12, Vol.26 (12), p.2375-2391

2015

Volltextzugriff (PDF)

A Dosing/Cross-Development Study of the Multikinase Inhibitor Sorafenib in Patients With Pulmonary Arterial Hypertension

Clinical pharmacology and therapeutics, 2010-03, Vol.87 (3), p.303-310

2010

Volltextzugriff (PDF)

Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib

Annals of oncology, 2012-08, Vol.23 (8), p.2103-2108

2012

Volltextzugriff (PDF)

Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor

European journal of cancer (1990), 2016-06, Vol.60, p.12-25

2016

Volltextzugriff (PDF)

The risk of nail changes with taxane chemotherapy: a systematic review of the literature and meta-analysis

British journal of dermatology (1951), 2015-09, Vol.173 (3), p.842-845

2015

Volltextzugriff (PDF)

The effect of cytotoxic chemotherapy on the risk of high-grade acneiform rash to cetuximab in cancer patients: a meta-analysis

Annals of oncology, 2011-11, Vol.22 (11), p.2366-2374

2011

Volltextzugriff (PDF)

The PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome

British journal of dermatology (1951), 2006-10, Vol.155 (4), p.852-854

2006

Volltextzugriff (PDF)

Olmutinib‐induced palmoplantar keratoderma

British journal of dermatology (1951), 2018-02, Vol.178 (2), p.e129-e131

2018

Volltextzugriff (PDF)

Regorafenib-associated hand–foot skin reaction: practical advice on diagnosis, prevention, and management

Annals of oncology, 2015-10, Vol.26 (10), p.2017-2026

2015

Volltextzugriff (PDF)

Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines

Annals of oncology, 2021-02, Vol.32 (2), p.157-170

2021

Volltextzugriff (PDF)

Taking it in the chin: vitamin K1 for the prevention of acneiform rash

Annals of oncology, 2018-04, Vol.29 (4), p.796-798

Lacouture, M.E.

2018

Volltextzugriff (PDF)

Analysis of dermatologic events in patients with cancer treated with lapatinib

Breast cancer research and treatment, 2009-04, Vol.114 (3), p.485-493

2009

Volltextzugriff (PDF)

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

Journal for immunotherapy of cancer, 2017-11, Vol.5 (1), p.95-28, Article 95

2017

Volltextzugriff (PDF)

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies

Annals of oncology, 2016-07, Vol.27 (7), p.1362-1362

2016

Volltextzugriff (PDF)

A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer

Annals of oncology, 2016-09, Vol.27 (9), p.1712-1718

2016

Volltextzugriff (PDF)

reply to the letter to the editor ‘Possible determinants of VSL#3 probiotic failure in preventing gastrointestinal adverse events associated with dacomitinib in patients with advanced non-small-cell lung cancer enrolled in ARCHER-1042 trial’ by Ceccarelli et al

Annals of oncology, 2016-11, Vol.27 (11), p.2138-2139

Lacouture, M.E.

2016

Volltextzugriff (PDF)

IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies

Annals of oncology, 2021-06, Vol.32 (6), p.736-745

2021

Volltextzugriff (PDF)

Oral lichenoid reactions associated with anti‐PD‐1/PD‐L1 therapies: clinicopathological findings

Journal of the European Academy of Dermatology and Venereology, 2017-10, Vol.31 (10), p.e464-e469

2017

Volltextzugriff (PDF)

Non‐invasive, in vivo, characterization of cutaneous metastases using a novel multimodal RCM‐OCT imaging device: a case‐series

Journal of the European Academy of Dermatology and Venereology, 2022-11, Vol.36 (11), p.2051-2054

2022

Volltextzugriff (PDF)

Outpatient dermatology consultations for oncology patients with acute dermatologic adverse events impact anticancer therapy interruption: a retrospective study

Journal of the European Academy of Dermatology and Venereology, 2020-06, Vol.34 (6), p.1340-1347

2020

Volltextzugriff (PDF)

Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor

Clinical and experimental dermatology, 2006-11, Vol.31 (6), p.783-785

2006

Volltextzugriff (PDF)

Alopecia in patients treated with molecularly targeted anticancer therapies

Annals of oncology, 2015-12, Vol.26 (12), p.2496-2502

2015

Volltextzugriff (PDF)

1 – 25 von 257

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(229)
Mit Volltextzugriff
(232)

Publikationsform

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(130)
Life Sciences & Biomedicine
(129)
Humans
(119)
Oncology
(57)
Female
(56)
Dermatology
(52)
Male
(52)
Middle Aged
(48)
Antineoplastic Agents - Adverse Effects
(44)
Aged
(43)
Adult
(37)
Neoplasms - Drug Therapy
(33)
Biological And Medical Sciences
(25)
Drug Eruptions - Etiology
(24)
Cancer
(23)
Quality Of Life
(20)
Medical Sciences
(19)
Aged, 80 And Over
(18)
Treatment Outcome
(18)
Medicine
(16)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

... seit 90 Tagen
(2)

Menü

Weitere Dienste

Einstellungen

Hand foot skin reaction in cancer patients treated with the multikinase inhibitors sorafenib and sunitinib

Immune‐related alopecia (areata and universalis) in cancer patients receiving immune checkpoint inhibitors

Validation and responsiveness of the English version of the Chemotherapy-Induced Alopecia Distress Scale (CADS) in breast cancer patients

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies

A Dosing/Cross-Development Study of the Multikinase Inhibitor Sorafenib in Patients With Pulmonary Arterial Hypertension

Development and validation of a prediction index for hand-foot skin reaction in cancer patients receiving sorafenib

Characterisation and management of dermatologic adverse events to agents targeting the PD-1 receptor

The risk of nail changes with taxane chemotherapy: a systematic review of the literature and meta-analysis

The effect of cytotoxic chemotherapy on the risk of high-grade acneiform rash to cetuximab in cancer patients: a meta-analysis

The PRIDE (Papulopustules and/or paronychia, Regulatory abnormalities of hair growth, Itching, and Dryness due to Epidermal growth factor receptor inhibitors) syndrome

Olmutinib‐induced palmoplantar keratoderma

Regorafenib-associated hand–foot skin reaction: practical advice on diagnosis, prevention, and management

Prevention and management of dermatological toxicities related to anticancer agents: ESMO Clinical Practice Guidelines

Taking it in the chin: vitamin K1 for the prevention of acneiform rash

Analysis of dermatologic events in patients with cancer treated with lapatinib

Managing toxicities associated with immune checkpoint inhibitors: consensus recommendations from the Society for Immunotherapy of Cancer (SITC) Toxicity Management Working Group

Toxicities of the anti-PD-1 and anti-PD-L1 immune checkpoint antibodies

A phase II study (ARCHER 1042) to evaluate prophylactic treatment of dacomitinib-induced dermatologic and gastrointestinal adverse events in advanced non-small-cell lung cancer

reply to the letter to the editor ‘Possible determinants of VSL#3 probiotic failure in preventing gastrointestinal adverse events associated with dacomitinib in patients with advanced non-small-cell lung cancer enrolled in ARCHER-1042 trial’ by Ceccarelli et al

IgE blockade with omalizumab reduces pruritus related to immune checkpoint inhibitors and anti-HER2 therapies

Oral lichenoid reactions associated with anti‐PD‐1/PD‐L1 therapies: clinicopathological findings

Non‐invasive, in vivo, characterization of cutaneous metastases using a novel multimodal RCM‐OCT imaging device: a case‐series

Outpatient dermatology consultations for oncology patients with acute dermatologic adverse events impact anticancer therapy interruption: a retrospective study

Inflammation of actinic keratoses subsequent to therapy with sorafenib, a multitargeted tyrosine-kinase inhibitor

Alopecia in patients treated with molecularly targeted anticancer therapies

Suchergebnisse filtern